Blue Horseshoe Stocks: KATE Recap & More

Kate Spade & Co. KATE – Recap

We closed out yesterday morning’s premarket report with a fresh options idea on KATE just following the company’s earnings report. While revenues were down, a healthy beat on profits led us to cast our lot in with the bulls.

We targeted KATE Weekly $20 and $21 Calls and were not disappointed with the outcome, with both sets of contracts providing ample opportunities for intraday gains.

The $20 Calls stopped just short of recording a double-bag move, running from 1.41 to 2.70, for a 91% rip. The $21s did manage that feat and then some, with a 131% pop from .65 to 1.50.


Fresh Options Ideas

VanEck Vectors Coal ETF (KOL) -  We want to put an extended watch on the coal industry just hours after breaking news of the signing of “Resolution 38″, which nullifies a recently enacted law barring coal miners from dumping project waste material in streams.

It’s a cost-cutting move that could benefit domestic coal producers in the long run, and could create some chances for us in the process. We want to add the KOL 03/17 $13 Calls, and  04/21 $14 Calls to our watchlist in the weeks and months ahead.

_____

Unilever PLC (UL) – Shares of UL spiked this morning on the heels of Unilever rejecting a $140B+ takeover bid. We’re looking to potentially take advantage of the resulting hype with an idea for possible daytrades.

We’re going to be keeping an eye on the UL Weekly $42.50-47.50 Calls for the chance at some quick-strike gain opportunities.


Extended Watchlist:
FNHI, KNSC, IDGC, VNUE, ARSN, BSTG

Blue Horseshoe Stocks: WFM Followup, ZSAN & More

Whole Foods Market, Inc. WFM – Options Update

Our primary focus for yesterday morning’s premarket report was our running options idea from last week. We were mentioning that the WFM 02/17 $30 and 30.50 Calls had begun to heat up, and we didn’t want to miss out on the activity that seemed ready to kick our idea into effect.

Our assumptions turned out to be accurate, with WFM stringing on another good session performance. The $30 Calls traded up from a low of .54 to .90 (+66%), while the $30.50′s made their way from .20-.42 (+110%).

We also mentioned that a break of the 50DMA at 30.76 for WFM would prompt us to look at contracts with a higher strike price and later expiration, the WFM 02/24 $31 Calls. We did indeed witness a breach of that price point toward the end of the session, and those calls came into play as well, running from 20-.35 for a chance at a nice 75% gain.

Should the solid uptrend WFM has been putting together continue into future sessions, these could be an ongoing item of interest for us.


Zosano Pharma Corp. ZSAN

ZSAN is a play we highlighted on Monday after the company reported that in its ZOTRIP pivotal efficacy study, its M207 transdermal migraine therapy patch met both primary, as well as secondary endpoints.

We mentioned that not only were we going to experience the effect of positive study data, but a technically ripening chart as well, leading us to put the stock on high alert in coming sessions.

It was a good decision, as the stock has really gained momentum this week, putting together some solid sessions. In fact, yesterday the stock closed as the NASDAQ’s top gainer of the day. We’ve watched as ZSAN has traded up from a low of 1.65 to yesterday’s new high of 3.49, representing an intraweek upswing of 112% Cheers to those of our readers who came along for the ride!



Opko Health, Inc. OPK

We put OPK on bottom watch earlier this month, and after a few sessions of further consolidation, the past four trading days have shown some convincing bottom-bounce action.

The stock ultimately found support at the 7.99-level last week, from which it has logged five straight sessions of higher highs and higher lows, reaching 8.66 yesterday. While that action only equates to an 8% increase, it’s the massive gap on the chart to the upside from just under $10 to just over $11.50. We’ll look for the stock to continue to build gradually and maintain the current trend in hopes of seeing a run toward a gap-fill.


FRESH OPTIONS IDEA:

Kate Spade & Co. KATE Weekly $20 and $21 Calls


Extended Watchlist:
RSII, MAXD, SRMX, CLSN, TPX

Blue Horseshoe Stocks: Options Update, GALT Recap & More

Whole Foods Market, Inc. WFM – Options Update

We just wanted to circle back for our WFM options idea that we submitted last week. We designated contracts with a 02/17 expiration instead of weeklies to give our idea time to develop and it ended up being a good call. Our targets were the WFM 02/17 $30 and 30.50 Calls.

Yesterday WFM had a morning pullback which was followed by a nice reversal, and the stock ended up bulling its way into the close near its high of day. The calls we signaled last week had a significant move as a result. The $30 Calls ran from .14-.52 (+271%), while the $30.50′s exploded from .05-.21 (+320%). We are going to want to keep them on our radar for the rest of the week into expiration.

Key resistance is at the 200DMA and 50DMA of 30.38 and 30.76, respectively. If WFM can crack the latter, we may look to roll our strike price up and push out another week to contracts expiring next Friday- particularly, the WFM 02/24 $31 Calls.



Galectin Therapeutics, Inc. GALT

We’ve now witnessed quite a run from GALT over the past few weeks, validating our previous reports on the stock wherein we contested that a serious run-up appeared likely.

It began with our report on 01/12, in which we noted GALT’s ripening chart, and surmised that forthcoming gains of 100% were not out of the question. We observed a low of .935 subsequent to that followed by a nice 38% push to 1.29 leading into our most recent report on GALT last Friday.

In that report we had this to say “We feel these gains are sustainable if GALT can manage to crack past the current 200DMA at 1.32. As you can see on the included snapshot, the chart continues to bear the look of potential for even further increases“.

Yesterday GALT met those expectations nicely with a run to a new high of 1.85, which marks an overall increase from our observed low of 98%, falling just a hair shy of our initial speculations. Yet, our prediction seems to be coming full circle this morning as the stock is gearing up to fill its gap on the chart that we pointed out in our initial report. One more bullish push will get us into double-bagger territory for this idea, and the stock may well make a run well into the 2.00-range.


Green EnviroTech Holdings Corp. GETH – Recap

We were quite pleased with the performance of GETH following our featured report yesterday morning, as the stock provided traders with a pair of solid intraday swings amid an onslaught of volume.

Right from the opening bell, GETH shot up from .165 to the high of day at .235, marking an initial rip of 42% The stock subsequently pulled back to a daily low at .1514, before surging up once more to .215, matching the morning’s 42% gain exactly.

All of this useful volatility was accompanied by massive volume on the order of 39X the monthly average, or 19X the 3-month average. It represented an all-time record high for shares of GETH traded in a single session!

Yesterday we had identified .15 as the key support level that needed to hold in order to make GETH interesting, and our sentiments in that regard haven’t changed.


Extended Watchlist:
ONOV, GAHC, NNSR, BG, WIX, GRPN, EVOK,

Blue Horseshoe Stocks: GETH Special Report


Green EnviroTech Holdings Corp. GETH – Special Report

As we mentioned in yesterday’s special reminder, we’ve got a new item of interest to present this morning. That stock is GETH, which has been building on the chart over the past few sessions. A number of key indicators point to a sizable potential upside for this play, but as we always do when we take an in-depth look at a company, we want to delve into the backstory a little bit before getting to the technical aspects of the chart.

While environmentally ‘green’ plays might not be the absolute height of trendiness anymore, we’re still always on the lookout for any company whose core business not only serves itself, but the best interest of the planet as well.

As human populations rocket ever-upward, solutions for the growing amounts of waste must be embraced by everyone. That’s why we’re particularly intrigued with GETH; for its waste-to-energy process that breaks down harmful waste and extracts the by-products, particularly high grade oil, and other useful materials for sale and re-use.

Used tires and waste plastics are two of the most voluminous and harmful constituents of the growing waste problem plaguing America’s landfills, and the GETH Technology Solution for waste-to-energy (and usable raw materials) specifically targets those two elements in their treatment facilities, whose input/output highlights are specified below:

  • A typical Gen 1 tire processing plant with a single ‘Cell’ is expected to be capable of processing up to 1,500,000 end-of-life tires per year and producing approximately 6,000 tons of carbon black, 51,000 barrels of oil, and 1,800 tons of steel from that feedstock.
  • A typical Gen 1 plastic processing plant with a single ‘Cell’ is expected to be capable of processing up to 33,800,000 pounds of waste plastic per year and producing approximately 99,000 barrels of oil.

We’re extremely interested in figures like those, as we said before, because they represent a win-win for GETH and the environment!

______

GETH CHART:

We find GETH to be attractive from a technical perspective as well, with a number of key points indicating the increasing likelihood of a significant push to the upside. 

The MACD is pinching in toward a bullish cross, while previous resistance coincides with the 50DMA of .232. A break past that point would leave a clear path to December’s swing-high of .40.

We’ve also prepared a short video presentation of the GETH Chart:

______

For More Info on GETH, visit: GreenEnvirotech.com

Blue Horseshoe Stocks: News Plays & Special Reminder

Aeterna Zentaris, Inc. AEZS

AEZS is gapping up this morning on the heels of some news. It’s been quite a few months since we last mentioned this stock. That was back in the fall, and we subsequently witnessed quite a surge from the stock after that.

Since then, so far in 2017 the stock has come down to record new annual lows, and recently has been making incremental increases off of that bottom. In light of today’s news, described below, we think it’s a good time to put AEZS back on a more intensive watch.

The company announced this morning, following a comprehensive review Phase 3 clinical data on Macrilen™ for the evaluation of growth hormone deficiency, that Macrilen™ demonstrated performance supportive of achieving registration with the FDA. The FDA has agreed to consider the Company’s conclusions during a Type A meeting, which is currently being scheduled. (>>View PR)


Zosano Pharma Corp. ZSAN

Speaking of fresh news plays, we also want to highlight the announcement coming from ZSAN this morning that presently has the stock gapping up in the premarket to the tune of 50%

This morning ZSAN reported that in its ZOTRIP pivotal efficacy study, the company’s M207 transdermal migraine therapy patch met both primary, as well as secondary endpoints. It certainly explains the premarket hoopla, and warrants our observation as we kick off a new trading week.

The chart also has some attractive features which we’ve pointed out on the snapshot below:


**SPECIAL REMINDER**

To wrap things up this morning, we want to leave our readers with a quick heads up on a big Tuesday coming up. We’ve got a special report coming out tomorrow prior to the opening bell. It could represent quite an opportunity, so tomorrow is definitely not the day to miss out on our premarket report!

Be sure to stay locked onto your email inboxes or BlueHorseshoeStocks.com tomorrow between 9:00 to 9:15AM, and lean on those refresh buttons!


Extended Watchlist:
MCIG, MYHI, ADVT, MJTK, QSIM, NK